CDTX (Cidara Therapeutics) Net Profit

Official company branding of Cidara Therapeutics Corp (CDTX)

The daily price chart for Cidara Therapeutics (CDTX) reflects asset value and profit dynamics that currently stand at -0.19. Cidara Therapeutics is undergoing a rigorous transformation, striving for survival by seeking new licensees following the sale of its primary asset. The business relies on outsourced manufacturing and testing to minimize costs while developing antiviral systems through an alliance with Janssen and the success of the drug Rezzayo.

CDTX (Cidara) Net Income history from 07/04/2022 to 01/17/2026

Analytical breakdowns and data insights for company Cidara Therapeutics Corp (CDTX)

- price and consensus price forecast:
Stock Quotes Cidara Therapeutics, Inc.|CDTX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Cidara Corp|CDTX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Cidara|CDTX - Company Net Assets|Market Value to Book Value Ratio cidara.com|CDTX - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Cidara Therapeutics|CDTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Cidara Corp|CDTX - Company Total Debt|Debts to Book Capitalization Cidara Corp|CDTX - Company Long-Term Debt|Short-Term Debt Volume Cidara|Quick Liquidity Indicator cidara.com
- net income and valuation multiples indicators:
CDTX - Net Profit
Summary company analysis:Cidara Therapeutics
Mass-produced product of Cidara Therapeutics Corp

This indicator reflects the daily dynamics of net income, allowing for a real-time assessment of cost management efficiency. By analyzing the company's profit margins, an investor can identify hidden cash gaps prior to the publication of quarterly reports. The metric is sensitive to any deviations in operating cash flow from planned values. For Cidara Therapeutics (CDTX), this is critical when monitoring the cash burn rate. The indicator correlates directly with the success of Cloudbreak trials and the receipt of partner tranches.

Main competitors

Net Income Gilead Corp|NVAX (Novavax, Inc.) - Net Profit|Net Profit curevac.com|Net Income VALN (Valneva)|VIR (Vir Biotechnology Inc) - Final Profit|SIGA Corp - Net Income|Emergent Bio - Company Net Income|Atea Pharmaceuticals - Net Profit|Net Financial Result Invivyd, Inc. IVVD|Enanta Pharmaceuticals, Inc. (ENTA) - Company Net Income|Inovio Pharmaceuticals, Inc. - Final Profit|Net Income HLVX|Net Profit Kalaris Tx|Company Net Income Dyadic International (DYAI)|Net Financial Result nanoviricides.com|Net Profit TLPH (Talphera)|COCP - Net Income|Traws Therapeutics - Net Profit|Net Financial Result Dogwood Therapeutics, Inc. DWTX|QLGN: Net Profit|Company Profit ALVR|VBIV (VBI Vaccines, Inc.) - Net Profit|Net Profit Virios|Company Net Income Vaxart, Inc. (VXRT)